Toxicological Research

Korean Society of Toxicology & Korea Environmental Mutagen Society (한국독성학회)
권호 표지

Local Irritation of DA-3285, Recombinant Human Erythropoietin

유전자재조합법으로 생산한 human erythropoietin(DA-3285)의 국소자극성에 관한 연구

  • Published : 1996.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

The local irritation studies of DA-3285, recombinant human erytropoietin(rHu-EPO), were carried out in rabbits after the following treatment; single application into the conjunctival sac of the eye, single subcutaneous injection, 7-day repeated subcutaneous injection and 8-day repeated infusion into the ear vein. Also, the local irritancy of DA-3285 leaked around vein was studied in mice by single perivascular injection. The results obtained were as follows. In the result of ocular irritation test, DA-3285 could be considered as a non-irritating material. In single and 7-day repeated subcutaneous irritation test, the irritancy of DA-3285 was not so much different from that of saline. The vascular irritancy of DA3285 by 8-day repeated infusion was negligible and similar to that of saline. And the irritancy of DA3285 by perivascular injection was comparable to that of saline. These results indicate that DA-3285 has no irritating activity when injected through subcutaneous or intravenous route for clinical practice as 3.5% solution.

Keywords

References

  1. J. Chemother. v.1 Skin and perivascular toxicity induced experimentally by doxorubicin Balsari,A.;Lombardo,N.;Ghione,M.
  2. Br. Med. J. v.295 Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having hemodialysis Casati,S.;Passerini,P.;Campise,M.R.;Graziani,G.;Cesana,B.;Persic,M.;Ponticelli,C.
  3. Kidney Int. v.32 Pharmacokinetics of recombinant human erythropoietin(r-HuEPO) administered to hemodialysis(HD) patients Egrie,J.C.;Eschbach,J.W.;McGuire,I.;Adamson,J.W.
  4. N. Engl. J. Med. v.276 Erythropoiesis in patients with renal failure undergoing chronic dialysis Eschbach,J.W.;Frunk,D.;Adamson,J.;Kuhn,I.;Scribner,B.H.;Finch,C.A.
  5. Br. Med. J. v.303 Assessment of pain after subcutaneous injection of erythropoietin n patients receiving haemodialysis Frenken,L.A.M.;Van Lier,H.J.;Gerlag,P.G.;Den Hartog,M.;Koene,R.A.P.
  6. Statistics for toxicologists in Principles and Methods of Toxicology Gad,S.C.;Weil,C.S.;Hayes,A.W.(ed.)
  7. Nature v.313 Isolation and characterization of genomic and cDNA clones of human erythropoietin Jacobs,K.;Shoemaker,C.;Rudersdorf,R.
  8. Lancet v.ii Recombinant erythropoietin and blood pressure Jacquot,C.;Ferragu-Haguet,M.;Lefebre,A.;Berthelot,J.M.;Peterlongo,P.;Castaigne,J.P.
  9. Scott. Med. J. v.17 Blood loss from cannulation sites during hemodialysis Lindsay,R.M.;Burton,J.A.
  10. Postgrad. Med. J. v.67 The use of erythropoietin in renal failure McDougall,I.C.;Hutton,R.D.;Coles,G.A.;Williams,J.D.
  11. Dialysis and transplantation v.8 Iron metabolism in end stage renal disease Merrill,R.H.
  12. Erythropoietin: A riview. J. Natl. Med. Assoc. v.86 Ridley,D.M.;Dawkins,F.;Perlin,E.
  13. Contib. Nephrol. v.88 Side effects during recombinant human erythropoietin therapy in 2000 ESRD patients Samtleben,W.;Ehmer,B.;Lutz-Knochenhauer,I.;Hagman,C.;Seigalla,P.;Gurland,H.J.
  14. Eur. J. Clin. Invest. v.21 Effect of human recombinant erythropoietin on anemia and dialysis efficacy in patient s undergoing continuous ambulatory peritoneal dialysis Steinhauer,H.B.;Lubrick-Birkner,I.;Dreyling,K.W.;Schollmeyer,P.
  15. Neth. J. Med. v.42 Erythropoietin : Mechanisms of action and indications for treatment Vreugdenhil,G.;Frenken,L.A.M.;Koene,R.A.P.
  16. Lancet v.ii Effect of human erythropoietin from recombinant DNA on the anemia of patients maintained by chronic hemodialysis Winearls,C.G.;Oliver,D.O.;Pippard,M.J.;Reid,C.;Downing,M.R.;Cotes,P.M.
  17. 日樂理紙 v.71 靜脈注射による血全性靜脈炎にる實驗的硏究 府川和永;伊藤義彦;三崎則幸;野村聰子
  18. 月刊藥事 v.16 no.6 藥劑に關する醫療事故について 赤石英;押田茂美;高橋由美子
  19. 醫藥ヅヤナル v.15 注射劑の局所障害性に關す試驗法(案) 厚生省資料
  20. 독성시험 표준작업지침서 안점막자극시험결과의 관찰 방법 및 판정기록 및 성적평가 국립보건안전연구원
  21. 국립보건안전연구원 고시 제94-3호 의약품등의 독성시험기준 국립보건안전연구원